contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


xbrane-har-publicerat-ars-och-hallbarhetsredovisningen-for-2025-redovisningen-sammanfattar-affarsverksamhet-finansiellt-resultat-samt-hallbarhetsarbetet

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Xbrane Biopharma is a biotechnology company focused on the development of biosimilars and biologics. The company is researching new therapies that can improve patient outcomes and quality of life. The products are used in the treatment of prostate cancer and endometriosis, as well as rare and serious eye diseases. Xbrane Biopharma was founded in 2008 and is headquartered in Solna, Sweden.

The name is an omen - pronounced “ex-brain” - this is where those who once had brains invest. Including, unfortunately, me.

So is this company the pharmaceutical industry’s own Summa Defence from Sweden?

It’s frustrating when the reverse split isn’t properly taken into account. But that company’s journey is still not amounting to anything.

Xbrane warns that it will be insolvent in a couple of months if the desired financing solutions are not reached and the company does not manage to out-license the Xdivane™ and/or XB003 candidates by the end of October.  As communicated on 1 August 2024 and given the previously communicated delay in FDA  approval of Ximluci® and the unforeseen termination of the license agreement with Biogen,  Xbrane Biopharma AB (publ) (“Xbrane” or the "Company”) has initiated a process to out-license  both Xdivane™ and XB003 for purposes of ensuring financing until envisioned positive  operational cash-flow in Q2 2025. It has now become obvious that the company needs to  finalize one of the above-mentioned license deals at satisfactory terms prior to the end of  October 2024 to fulfill the Company’s working capital requirements from beginning of  November 2024 and onwards.             storage.mfn.se              xbrane-provides-update-on-the-ongoing-out-licensing-of-xdivane-nivolumab-biosimilar-candidate-and-xb003-cimzia-r-biosimilar-candidate-and-its-financial-position.pdf

How have you handled your holdings in this stock, @Zolt? I only just came across this company and the slide has been quite significant, especially since August 2023. Heavy dilution and high cash burn, but could 2025 finally be their year? Market cap is now approx. €30m.

It’s hard to see any profitable future for this Ximluci. From what I’ve researched, off-label Bevacizumab is still cheaper, and on the other hand, aflibercept and faricimab are better and longer-acting. There simply isn’t a market niche.

xbrane.com              » Xbrane and STADA partner with Valorum Biologics to commercialize...                               XBRANE AND STADA PARTNER WITH VALORUM BIOLOGICS TO COMMERCIALIZE RANIBIZUMAB BIOSIMILAR CANDIDATE IN THE US  Based on this, could one think that obtaining FDA approval looks quite promising?

Xbrane Biopharma

” Utvecklingen av Xdivane™ fortsätter enligt plan och vi planerar för att Xdivane™ skall vara en av de första biosimilar produkterna som lanseras globalt på en gigantisk PD1 hämmarmarknad med...

<div class="mfn-preamble"><p><strong>” Utvecklingen av Xdivane™ fortsätter enligt plan och vi planerar för att Xdivane™ skall vara en av de första biosimilar produkterna som lanseras globalt på en gigantisk PD1 hämmarmarknad med ett projicerat värde på 400 miljarder kronor”, säger Anders Tullgren, styrelseordförande.</strong></p></div><div class="mfn-body"><p>Xbrane Biopharma AB:s årsredovisning för 2025 finns från och med idag tillgänglig på bolagets webbsida, www.xbrane.com.<br>Årsredovisningen inkluderar bolagsstyrningsrapport samt hållbarhetsrapport för 2025 och kommer att distribueras till de aktieägare och andra som uttryckligen begärt att få denna. Den kan även beställas från Xbrane Biopharma på adressen:</p><p>Xbrane Biopharma AB<br>Scheeles väg 5<br>171 65 Solna<br>Eller via e-mail: ir@xbrane.com</p></div><div class="mfn-footer mfn-contacts mfn-a61f5cf72e83"><p><strong class="mfn-heading-1">Kontakter</strong></p><hr><p>Martin Åmark, VD<br>E: <a href="mailto:martin.amark@xbrane.com" rel="noopener">martin.amark@xbrane.com</a></p><p>Jane Benyamin, Finanschef/IR <br>E: <a href="mailto:jane.benyamin@xbrane.com" rel="noopener">jane.benyamin@xbrane.com</a></p></div><div class="mfn-footer mfn-about mfn-1cc8f17c2be2"><p><strong class="mfn-heading-1">Om oss</strong></p><hr><p>Xbrane Biopharma AB utvecklar biologiska läkemedel baserade på en patenterad plattformsteknologi som ger betydligt lägre produktionskostnader jämfört med konkurrerande system. Xbrane har en portfölj av biosimilarkandidater som tillsammans adresserar 23 miljarder EUR i förväntad årlig peak-försäljning av respektive referensläkemedlet. Den ledande biosimilarkandidaten Ximluci® är godkänd i Europa och lanserades under 2023. Xbranes huvudkontor ligger i Solna, strax utanför Stockholm. Xbrane är noterat på Nasdaq Stockholm under tickern XBRANE. För mer information, besök www.xbrane.com</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-vpml"><p><em>Denna information är sådan information som Xbrane Biopharma är skyldigt att offentliggöra enligt lagen om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 2026-03-31 10:00 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Bifogade filer</strong></p><hr><p><a class="mfn-primary" href="https://storage.mfn.se/52a5f2b5-d75d-4136-ab74-810f1ffba32a/xbrane-ar-2025.pdf" rel="noopener">Xbrane AR 2025</a><br><a href="https://storage.mfn.se/28ac51ae-2301-4bd5-9474-2d2a02fd606a/xbra-2025-12-31-1-sv.xbri" rel="noopener">xbra-2025-12-31-1-sv</a><br><a href="https://storage.mfn.se/b1809fd1-27e6-4993-b8d3-edb5e801cd44/xbra-2025-12-31-1-sv_preview.xhtml" rel="noopener">xbra-2025-12-31-1-sv_preview</a></p></div>

Xbrane har publicerat års- och hållbarhetsredovisningen för 2025. Redovisningen sammanfattar affärsverksamhet, finansiellt resultat samt hållbarhetsarbetet.